Table 2.
Treatment persistence: time-to-event analysis
| Treatment | Primary analysis cohort | Biologic naive | Biologic exposed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Treatment episodes, n | Persistence, months, median (95% CI) | Persistence rate, % | Treatment episodes, n (%) | Persistence, months, median (95% CI) | Persistence rate, % | Treatment episodes, n (%) | Persistence, months, median (95% CI) | Persistence rate, % | |||||||
| 1 year | 2 years | 5 years | 1 year | 2 years | 5 years | 1 year | 2 years | 5 years | |||||||
| Adalimumab | 1046 | 22.2 (18.8–25.4) | 64.6 | 47.9 | 26.8 | 862 (82.4) | 23.9 (20.6–29.4) | 66.9 | 50.0 | 29.9 | 184 (17.6) | 12.4 (10.5–17.6) | 52.6 | 37.0 | 11.9 |
| Etanercept | 974 | 16.3 (14.5–19.0) | 57.8 | 39.7 | 16.8 | 904 (92.8) | 16.7 (15.0–19.8) | 59.1 | 40.8 | 17.3 | 70 (7.2) | 9.9 (6.7–17.6) | 42.6 | 25.3 | 10.1 |
| Ixekizumab | 50 | NRa | 81.3 | – | – | 6 (12.0) | 13.4 (13.4–∞) | – | – | – | 44 (88.0) | NR | 78.4 | – | – |
| Secukinumab | 394 | NRa | 75.9 | 58.5 | – | 202 (51.3) | NR | 79.0 | 64.1 | – | 192 (48.7) | 25.7 (20.2–∞) | 72.5 | 52.0 | – |
| Ustekinumab | 488 | 49.3 (38.0–59.1) | 79.9 | 64.8 | 41.6 | 254 (52.0) | 55.4 (45.6–64.8) | 82.6 | 66.8 | 46.6 | 234 (48.0) | 40.3 (32.6–58.7) | 76.7 | 62.6 | 33.0 |
CI Confidence interval, NR not reached
a50 patients did not discontinue treatment (equivalent to median persistence) within the time frame of the study